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OBJECTIVE — Todeterminethepredictorsofprogressionofcalciﬁedatherosclerosisandthe
effect of intensive glycemic control on this process in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — As part of the Risk Factors, Atherosclerosis,
andClinicalEventsinDiabetes(RACED)substudyoftheVeteransAffairsDiabetesTrial(VADT),
197 and 189 individuals with type 2 diabetes received baseline and follow-up computed tomo-
graphicscansformeasurementofcoronaryandabdominalarterycalcium,respectively.Standard
and novel risk factors were assessed at baseline, and progression of calciﬁed atherosclerosis was
determined by several methods. Progression was deﬁned both as a categorical (square root
increase of volumetric scores 2.5 mm
3) and continuous variable. In addition, annualized
percent change of volume scores was determined.
RESULTS — After an average follow-up of 4.6 years, 75% of individuals demonstrated
coronary (CAC) and abdominal artery calciﬁcation (AAC) progression. Progression increased
with higher baseline calcium categories but was not inﬂuenced by standard risk factors. How-
ever, the albumin-to-creatinine ratio (ACR) (P  0.02) and lipoprotein-associated phospho-
lipase A2 (Lp-PLA2)( P  0.01) predicted progression of CAC, and these results were not altered
by adjustment for age and other traditional risk factors. Treatment assignment (intensive versus
standard) within the VADT did not inﬂuence CAC or AAC progression, irrespective of baseline
calcium category.
CONCLUSIONS — In patients with long-standing type 2 diabetes, baseline CAC, Lp-PLA2,
and ACR predicted progression of CAC. Intensive glycemic control during the VADT did not
reduce progression of calciﬁed atherosclerosis.
Diabetes Care 33:2642–2647, 2010
A
therosclerosis is accelerated in pa-
tients with type 2 diabetes and un-
derlies their higher incidence of
cardiovascular disease (CVD) events.
Noninvasive imaging of atherosclerosis,
as measured by coronary (CAC) and ab-
dominal aortic artery calciﬁcation (AAC),
provides a useful tool to assess coronary
and systemic atherosclerosis burden. Al-
though both CAC and AAC scores have
been shown to be strong predictors of
subsequent cardiovascular morbidity and
mortality (1,2), only a few studies have
investigated the association of calcium
progression with future events (3,4), and
there is less certainty about the implica-
tions of progression of vascular calciﬁca-
tion (5). In a study of asymptomatic
subjects, CAC progression 15% was a
strong predictor of future myocardial in-
farction (4). In addition, monitoring of
CAC and AAC progression has been sug-
gested as a possible method for assessing
the treatment efﬁcacy of medicines to
reduce CVD risk (6,7). Therefore, an un-
derstanding of the determinants of pro-
gression of vascular calcium may provide
insight into atherogenesis and develop-
ment and treatment of CVD.
Although the relationship of risk fac-
torswithextentofvascularcalciﬁcationis
relatively well recognized, determinants
of progression, particularly in type 2 dia-
betes, have been less well studied. The
large Multi-Ethnic Study of Atherosclero-
sis (MESA) reported that most standard
cardiovascular risk factors were modestly
associated with progression of CAC (8) in
individuals without known CVD, and di-
abetes and the baseline calcium score
were strong predictors of CAC progres-
sion (8). In patients with diabetes, base-
line CAC, blood pressure, central
adiposity,urinealbumin-to-creatininera-
tio (ACR), and suboptimal glycemic con-
trol have been reported as predictors of
CAC progression (9–11). However, AAC
progression has been investigated only in
patientswithend-stagerenaldisease(12).
Inaddition,althoughtherearestrongcor-
relations between cross-sectional mea-
sures of CAC and AAC and they share
associations with several standard risk
factors, clear differences in association of
risk factors with the extent of CAC and
AAC exist (13). Whether determinants of
CAC and AAC progression differ in those
with or without type 2 diabetes is not
known, as previous studies have not ad-
dressed this question within the same co-
hort. Moreover, although mounting
evidence supports the role of inﬂamma-
tion in atherogenesis, the relationship of
subclinical inﬂammatory markers with
the burden and progression of calciﬁed
atherosclerosis is still unclear (14). Fi-
nally, although the Diabetes Control and
Complications Trial/Epidemiology of Di-
abetes Interventions and Complications
(DCCT/EDIC) showed that intensive gly-
cemic treatment was associated with
lower incidence of CVD over time (15),
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progression of calciﬁed atherosclerosis in
type 2 diabetes has not been directly
examined.
In this prospective VADT substudy,
we characterized the pattern of both CAC
and AAC progression in older patients
withlong-standingtype2diabetes.Inad-
dition, we determined the relationship of
both standard and novel inﬂammatory
riskmarkers(C-reactiveprotein,interleu-
kin-6 [IL-6], adiponectin, and lipopro-
tein-associated phospholipase A2 [Lp-
PLA2]) with CAC and AAC progression.
Finally, we provide the ﬁrst report of the
effect of intensive glycemic control on
progression of CAC and AAC in patients
with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Data for this study use
baseline examinations and follow-up im-
aging from participants in the Risk Fac-
tors, Atherosclerosis, and Clinical Events
in Diabetes (RACED) study, which is a
seven-site substudy (1) of the VADT. The
VADT study design, exclusion/inclusion
criteria,andstudymeasuresandactivities
have been described in detail previously
(16), and further information is provided
in the supplementary material (available
in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc10-
1388/DC1). Of the 301 subjects partici-
pating in the RACED study with both
CAC and AAC scans at baseline, 197 sub-
jectscompletedfollow-upCACscansand
189 subjects completed follow-up AAC
scans. The main reasons for not obtaining
follow-up scans in the other RACED par-
ticipants included participant relocation,
electivewithdrawalfromstudy,illness,or
death.However,therewerenosigniﬁcant
differences in baseline characteristics be-
tween the subjects with no follow-up
scans and those with repeat scans at fol-
low-up (Table 1).
Laboratory methods
Lp-PLA2 mass was measured by an en-
zyme immunoassay (PLAC test; dia-
Dexus) in plasma with intra-assay and
interassaycoefﬁcientsofvariationranging
from 4% to 6% and 6% to 9%, respec-
tively. Additional laboratory methods are
provided in supplementary material.
Assessment of coronary and
abdominal artery calcium scores
Coronary and abdominal aortic calcium
were determined by using either electron
beam or multidetector computed tomo-
graphic cardiac scanning as described
(1,17). The volumetric score as described
by Callister et al. (18) was used to assess
progression of vascular calcium.
Deﬁnitions of progression
Progression of vascular calcium was de-
termined using three different ap-
proaches. First, progression was
calculated as the difference between the
square root (dSQRT) transformation of
the follow-up and baseline volumetric
calcium scores (19). Second, progression
as a dichotomous variable was deﬁned as
present when the dSQRT of volume
scores was 2.5 mm
3, as this cutoff pro-
vides an estimate that is unbiased with
respect to baseline calcium (20). Finally,
for comparison with earlier studies of cal-
cium progression, the annualized percent
change in volumetric calcium scores was
also calculated (3). Additional details are
provided in the supplementary material.
Statistical analysis
Statistical analyses were performed with
the SAS statistical package (release 9.1;
SAS Institute, Cary, NC). Means  SD,
medians (25–75%), and proportions are
reported. Between-group differences in
normally distributed continuous vari-
ables were assessed with t tests, Mann-
Whitney U tests were used for variables
with skewed distributions, and 
2 tests
were used for proportions. To determine
predictorsofprogression,univariableand
multivariable linear regression analyses
wereperformedseparatelyforthetwode-
pendent variables (dSQRT of CAC and
AAC). Predictor variables with skewed
distributions were log-transformed to ap-
proachanormaldistribution.Sexwasnot
included as one of covariates, because
only 7% (n  14) of the study population
were women. With exclusion of women
from the analyses, the results did not
change appreciably. To assess the possi-
bility of effect modiﬁcation, pairwise in-
teraction terms of predictor variables
were evaluated. However, none of the in-
teraction terms were signiﬁcant and,
therefore, were not included in the ﬁnal
models.
RESULTS
Baseline characteristics
The study population included 197 sub-
jects with a mean age of 61  9 years,
diabetes duration of 12  8 years, BMI of
314kg/m
2,andA1Cof9.21.3%.Of
the subjects, 68% (n  133) reported
Table 1—Baseline characteristics
With scans
Without scans Standard Intensive
n 104 93 104
Standard risk factors
Age (years) 61  96 1  96 1  9
NHW (%) vs. others 73 61 62
Smoker (%) 14 12 18
Hypertension (%) 77 84 80
Prior CVD (%) 37 37 39
BMI (kg/m
2) 31.2  4.3 31.4  4.2 31.4  4.5
Duration (years) 12  81 3  81 2  8
A1C (%) 9.2  1.3 9.2  1.4 9.5  1.5
Total cholesterol (mg/dl) 178  38 183  42 179  33
LDL cholesterol (mg/dl) 100  31 108  32 106  29
HDL cholesterol (mg/dl) 36  11 38  11 36  10
Triglycerides (mg/dl) 167 (126–266) 156 (117–208) 163 (113–233)
Total cholesterol-to-HDL ratio 5  25  15  2
Novel risk factors
ACR (mg/g) 21 (7- 83) 14 (4–36)* 18 (6–55)
C-reactive protein (mg/l) 3.1 (1.7–5.1) 2.5 (1.4–5.8) 3.3 (1.6–7.8)
IL-6 (pg/ml) 3.2 (2.1–5.1) 2.7 (1.8–5.7)† 3.3 (2.3–4.8)
Adiponectin (mg/l) 5.1 (3.1–7.9) 4.7(2.9–7.5) 5.7 (3.5–9.4)
Lp-PLA2 (ng/ml) 294 (241–351) 284 (35–338) 289 (241–362)
Baseline CAC score 239 (17–808) 267 (27–981) 301 (23–849)
Baseline AAC score 917 (125–3,508) 848 (189–4,401) 1,674 (193–4,442)
Data are means  SD, medians (25%–75%), or %. *P  0.05; †P  0.01 vs. standard group.
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race, and other categories (others) in-
cluded Hispanic whites (n  32), African
Americans (n  24), and Asians or those
of mixed races (n  8). The majority had
a history of hypertension (81%) and 37%
had prior CVD. Median (25–75%) base-
line CAC and AAC scores were 258 (18–
872) and 922 (173–3,841), respectively.
Except for slightly lower urinary ACR
(P  0.02) and IL-6 (P  0.01) levels in
the intensive treatment group, there were
nosigniﬁcantdifferencesbetweenthetwo
treatment groups at baseline (Table 1).
Progression of vascular calcium
After a mean follow-up time of 4.6  0.6
years in the whole cohort, the median
(25–75%) CAC progression was 6.5 mm
3
(3.3–11.2 mm
3) and the median annual-
ized percent change in CAC was 20% (9–
41%). The AAC progression was 11 mm
3
(5–18 mm
3) and the annualized percent
change in AAC was 17% (6–35%). The
cumulative incidence of progression
(2.5 mm
3) was 78 and 81% for CAC
and AAC, respectively. Approximately
5% (9 subjects) and 12% (22 subjects) of
subjects showed a decrease in CAC or
AAC over time, respectively. A careful re-
view of paired CAC scans showing a de-
creaseindicatedthateightofnineresulted
from poor images, mislabeled scans, or
scan artifacts (e.g., surgery clips). We
therefore believe negative scans do not
generally represent true regression and
may interfere with identiﬁcation of rela-
tionships of determinants with progres-
sion of calciﬁed atherosclerosis.
Subsequent data analyses are reported af-
ter exclusion of individuals with negative
values.
To determine whether progression
varied according to severity of baseline
calciﬁcation, baseline CAC and AAC Ag-
atston scores were divided into three cat-
egories: 0–10, 10–100, and 100 for
CAC and 0–100, 100–1,000, and
1,000 for AAC. The extent of CAC and
AAC progression increased signiﬁcantly
(P  0.01) with higher baseline CAC or
AAC categories (supplementary Fig. 1,
availableinanonlineappendix).Interest-
ingly, the majority (59%) of subjects with
a CAC Agatston score of 0 at baseline
maintainedaCACscoreof0atfollow-up,
and the median (25–75%) Agatston score
at follow-up in the remaining 41% was
only 15 (8–34). Of the 23 subjects with
an AAC Agatston score of 0 at baseline,
the score in 35% did not increase further
at follow-up, and the median AAC Agat-
ston score in the remaining 65% was 44
(9–172).
Predictors of progression
Univariable predictors of CAC progres-
sion were NHW ethnicity (P  0.01), Lp-
PLA2 mass (P  0.01), and ACR (P 
0.05). Pack-years smoking (P  0.04),
prior CVD (P  0.03), Lp-PLA2 mass
(P  0.04), and lower A1C (P  0.05)
predicted progression of AAC (supple-
mentary Table 1, available in an online
appendix). No other standard or novel
risk factor was associated with progres-
sion of CAC and/or AAC in univariable
models.AsshowninTable2,afteradjust-
ment for standard risk factors (model 1),
Lp-PLA2 mass (P  0.01) and ACR (P 
0.02) remained signiﬁcant predictors of
CAC progression. After adjustment for
standard risk factors, the association be-
tween Lp-PLA2 mass and AAC progres-
siondidnotremainsigniﬁcant(P0.22)
(data not shown). Adjustment for base-
linecalcium,treatmentassignment,mean
on-trial variables BMI, A1C, total choles-
terol-to-HDLratio,andACR,andontrial-
medications (statins, antihypertensive
agents,ACEinhibitors,andangiotensinII
receptorblockers)thatmightconceivably
inﬂuence outcomes did not appreciably
change these conclusions (models 2–5).
Plasma levels of Lp-PLA2 were also mea-
sured 9 months into the study, but they
did not change signiﬁcantly from base-
line. Furthermore, adjustment for the
9-month levels or the mean of baseline
and 9-month levels did not change the
results (data not shown).
Effect of intensive glycemic
treatment on progression
Treatment assignment did not signiﬁ-
cantly inﬂuence either CAC or AAC pro-
gression, whether determined by
cumulative incidence (supplemental Fig.
2A, available in an online appendix), an-
nual percent change (supplemental Fig.
2B), or absolute progression (Fig. 1).
Moreover, no effects of treatment assign-
ment were seen for progression of either
CAC or AAC at any level of baseline cal-
cium (Fig. 1). Similarly, even though
there was evidence for different rates of
CAC progression between NHW and
other ethnic/racial groups (supplemen-
tary Table 1) treatment assignment did
not inﬂuence CAC or AAC progression in
either of these groups.
CONCLUSIONS — The present
study, which characterized the nature of
progression of both CAC and AAC in
older patients with a relatively long dura-
tion of type 2 diabetes, revealed several
important ﬁndings. The incidence and
yearlyrelativeratesofbothCACandAAC
progression were quite high in our study,
with 80% of individuals demonstrating
true progression (20). These rates are in
line with previously described progres-
sion rates in type 2 diabetic patients who
had a myocardial infarction (4) and pre-
sumably help explain the high rate of
CVD events reported in the VADT. Be-
cause this is the ﬁrst description of AAC
progression in type 2 diabetes, we cannot
compare the results with previous stud-
ies.However,thesehighAACprogression
rates are certainly consistent with the rel-
atively high prevalence of peripheral vas-
cular disease in individuals with many
years of diabetes. One strength of this
study is the long interval between scans
and the extensive absolute change in cal-
cium that occurred, providing additional
conﬁdence in the estimates of the rates of
vascular calcium progression.
As has been reported in cross-
sectionalstudiesofcalciumaccumulation
(13,21), there were differences between
CAC and AAC in relationships between
risk factors and progression of calcium.
Although age, BMI, duration of diabetes,
Table 2—Multivariable linear regression models for predictors of CAC progression
Regression coefﬁcients
Model 1 Model 2 Model 3 Model 4 Model 5
Log(ACR) 0.72  0.32* 0.62  0.29* 0.61  0.29* 1.02  0.42† 0.86  0.42*
Log(Lp-PLA2) 4.57  1.88* 3.77  1.69* 3.77  1.70* 4.55  1.73† 4.51  1.73*
Data are means  SEM. All models include log(ACR) and log(Lp-PLA2) at the same time. Model 1: adjusted
for age, diabetes duration, BMI, ethnicity (NHW vs. others), pack-years smoking (number of packs of
cigarettesperdaynumberofyearssmoked),hypertension,priorCVD,A1C,andtotalcholesterol-to-HDL
ratio.Model2:adjustedformodel1baselineCAC.Model3:adjustedformodel2treatmentassignment.
Model 4: adjusted for model 3  mean of on-trial variables (A1C, BMI, ACR, and total cholesterol-to-HDL
ratio).Model5:adjustedformodel4on-trialmedication(statins,antihypertensiveagents,ACEinhibitors,
and angiotensin II receptor blockers). *P  00.05; †P  0.01.
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pertensionand/orpriorCVDwereassoci-
ated with the extent of CAC and AAC
(datanotshown),theydidnotpredictthe
progression of CAC in univariable mod-
els. In contrast, age, pack-years smoking,
and history of prior CVD predicted AAC
progression in univariable models. Inter-
estingly in a cross-sectional study, NHW
ethnicity, which we had previously re-
ported was associated with increased
CAC and AAC (17), was related to pro-
gression of CAC, but not of AAC, in uni-
variableanalysis.HigherA1Cvalueswere
associated with reduced progression of
both CAC and AAC. However, after mul-
tivariable adjustment, none of the above
baseline standard risk factors remained
signiﬁcant predictors of either CAC or
AACprogression.Onemayspeculatethat
vascular calciﬁcation is in part a response
to vascular injury, inﬂammation, and
atherogenesis initiated by standard risk
factors. Once a more advanced athero-
sclerotic plaque, composed of modiﬁed
lipoproteins, cellular debris, and acti-
vatedandproinﬂammatoryvascularcells,
has developed, the atherogenesis and ec-
topic calciﬁcation process in vessels be-
comes self-propagating, and the role for
standard risk factors diminishes. This
possibility is consistent with the fact that
preexisting calcium in each vascular bed
was a strong predictor of CAC or AAC
progression in this and other studies (9–
11). In fact, individuals with a CAC or
AAC score of 0 demonstrated either no or
modest levels of calciﬁed atherosclerosis
progression.
Toexplorethepossibilitythatlesstra-
ditional CVD risk factors may contribute
toprogressionofcalciﬁedatherosclerosis,
weevaluatedseveralofthemorecommon
novel markers. Whereas C-reactive pro-
tein, IL-6, and adiponectin were not
foundtobesigniﬁcantlyrelatedtoCACor
AAC progression, Lp-PLA2 mass pre-
dicted progression of CAC after adjust-
ment for other covariates. An association
ofLp-PLA2withAACprogressionalsoex-
isted but was weaker in the multivariable
model. Although this is the ﬁrst study to
assess the associations of Lp-PLA2 mass
withCACorAACprogression,onerecent
study reported an association between
Lp-PLA2 mass and cross-sectional mea-
sures of calciﬁed coronary plaque (22).
The strong association of Lp-PLA2with cal-
ciﬁedatherosclerosisprogressionsuggestsa
unique role for the postulated proinﬂam-
matoryLp-PLA2enzymeinongoingplaque
formation in type 2 diabetes. Numerous
studies have reported an association be-
tweenLp-PLA2massandactivitywithCVD
events (21) and have suggested that Lp-
PLA2 may alter atherosclerotic plaque
stability. Lp-PLA2 is produced by inﬂam-
matorycells,includingmacrophageswithin
atherosclerotic plaques, and it binds pri-
marily to apolipoprotein B-containing li-
poproteins such as LDL. After LDL
oxidation, Lp-PLA2 rapidly hydrolyzes oxi-
dized phospholipids, leading to the genera-
tion of two inﬂammatory products,
lysophosphatidylcholine and the released
oxidized fatty acid (23), within the vessel
wall. By virtue of this proinﬂammatory ac-
tivity, its local production by inﬂammatory
cells, and its close association with artery
wall lipoproteins, LP-PLA2 is well posi-
Figure 1—Progression of CAC or AAC by treatment assignment. A: Median and 25th–75th
percentiles of CAC progression by treatment group in all participants and by baseline CAC
categories.ThePvalueforthecomparisonbetweenthetreatmentgroupswasnotsigniﬁcantinall
participants or in any baseline CAC categories. B: Median and 25th–75th percentiles of AAC
progressionbytreatmentgroupinallparticipantsandbybaselineAACcategories.ThePvaluefor
the comparison between the treatment groups was not signiﬁcant in all participants or in any
baseline AAC categories.  , standard group; f, intensive treatment group.
Saremi and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 2645tionedtoexacerbatetheongoinginﬂamma-
toryprocesswithinestablishedplaquesand
thus promote further atherogenesis. Be-
cause oxidative stress is commonly in-
creased in the presence of hyperglycemia
anddyslipidemia,Lp-PLA2mayhaveapar-
ticularly important role in atherosclerosis
progression in type 2 diabetes.
The present study suggests that ACR
is a predictor of CAC progression, even
after adjustment for other baseline risk
factors. Consistent with these data, an as-
sociationbetweenACRandCACprogres-
sion has been reported in patients with
type 2 diabetes (10). We note that ACR
levels were below microalbuminuric
ranges in the majority (66%) of partici-
pantsinthepresentstudy,suggestingthat
ACR may be a sensitive indicator or me-
diator of vascular processes that promote
calciﬁed atherosclerosis.
In the VADT, intensive glycemic con-
trol did not reduce the development of
CVD events (24), and it remains un-
known whether one explanation for this
treatment strategy failure was an inability
to slow atherosclerosis. The current re-
sults support this possibility, because in-
tensive glycemic control did not reduce
progression of calciﬁed atherosclerosis
over the time frame of this study. These
novel results may also have implications
for the Action to Control Cardiovascular
RiskinDiabetes(ACCORD)andActionin
Diabetes and Vascular Disease Preterax
and Diamicron Modiﬁed Release Con-
trolled Evaluation (ADVANCE) studies,
in which intensive glucose-lowering ther-
apy also failed to reduce CVD events.
These results do not address whether im-
proved glucose control may have suc-
ceeded in favorably altering lesion
composition or speciﬁcally slowing soft
plaque progression. However, these fa-
vorable outcomes seem unlikely, given
the rapid rate of calciﬁed atherosclerosis
progression in both groups. Neither CAC
norAACprogressionwasslowedininten-
sively treated groups at any beginning
level of calcium, suggesting that the ben-
eﬁt of intensive glycemic control, origi-
nally found in the subset of individuals
with less advanced disease (25), may be
the effect of improved glucose values on
thrombogenesis or plaque rupture. Some
support for this notion may be drawn
from the relatively rapid divergence in
survival curves between individuals re-
ceiving intensive or standard glucose-
lowering treatment (24). However, this
hypothesis needs conﬁrmation in future
studies.
Several study limitations deserve
mention. The RACED cohort consisted
mainly of older men, limiting the ability
to generalize our ﬁndings to a broader di-
abetes population. Approximately one-
thirdoftheinitialcohortwasnotavailable
for repeat scans, raising the possibility
that they were less healthy and their ex-
clusion could have affected the results.
However, the baseline characteristics of
theseindividualsdidnotdifferfromthose
with follow-up scans (Table 1) and their
incidenceofCVDeventsduringthestudy
was similar (32 vs. 28%; P  0.53). A
larger sample size may also have permit-
ted detection of additional predictors of
progression that were less robust than
ACR and Lp-PLA2. Because our Lp-PLA2
measurementwaslimitedtomass,further
studies will be needed to determine
whether Lp-PLA2 activity would also pre-
dict CAC progression. This study of base-
line predictors of progression of calciﬁed
atherosclerosis was conducted within a
trial of glucose control, which has the po-
tential to induce greater variation during
the trial in certain risk factors in the in-
tensively treated groups, thereby possibly
lessening the association with CAC or
AAC progression. However, standard
CVD risk factors were equally well con-
trolled in both treatment groups during
the study (24). Although glucose levels
differed between groups, neither glyce-
miccontrolnortreatmentassignmentwas
a relevant predictor of CAC or AAC pro-
gression. Finally, additional sensitivity
testingusingmultivariablemodels,which
included average on-trial conventional
risk factors and A1C, relevant medication
use, or inclusion of subjects showing re-
gression in calcium scores, did not appre-
ciably change the results.
In summary, in this older group of
individualswitharelativelylongduration
oftype2diabetesandahighprevalenceof
CVD, the progression of CAC and AAC
proceeded at a remarkably high rate. Of
importance, intensive glycemic treatment
didnotappeartoslowtherateofprogres-
sion, and this was true even in those with
very low baseline CAC. This result pro-
vides further support for the limited role
that improved glycemic control may have
on slowing atherosclerosis and may con-
tribute to our understanding of why the
VADT and other large trials of intensive
glycemic control did not succeed in re-
ducing CVD events. Although baseline
standard risk factors were not identiﬁed
as being associated with progression of
calciﬁed atherosclerosis, Lp-PLA2 mass
signiﬁcantly predicted CAC progression
even after adjustment for standard risk
factors and predicted AAC progression in
theunivariablemodel.Thesedatasuggest
that in the setting of excellent control of
lipids and blood pressure, Lp-PLA2 pro-
videsadditionalpredictionofprogression
of calciﬁed atherosclerosis beyond stan-
dardriskfactors.Theseoverallstudyﬁnd-
ings provide novel information about the
nature of progression of calciﬁed athero-
sclerosis and relevant determinants of
progression in type 2 diabetes and dem-
onstrate that within the time frame of this
study, intensive glucose lowering was rel-
ativelyineffectiveinreducingprogression
of calciﬁed atherosclerosis in this subset
of the VADT.
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